Vigilance includes:
1° For user healthcare professionals mentioned in Article L. 5232-4, the reporting to the Agence française de sécurité sanitaire des produits de santé of any incident consisting of a failure or alteration in the characteristics or performance of the health products mentioned in this section, or an inadequacy in the labelling or instructions for use, likely to result in adverse effects on the health of individuals;
2° For the Agence française de sécurité sanitaire des produits de santé:
a) The recording, evaluation and use of information collected with a view to protecting human health;
b) The carrying out of studies or work concerning the causes of incidents observed and relating to the quality or safety of use of the health products mentioned in this section;
c) The monitoring of corrective actions decided upon;
3° For manufacturers, publishers, distributors and users, the communication of the information mentioned in article R. 5232-18.